Biotech Hot Stocks: Baxalta Incorporated (NYSE:BXLT), Exelixis, Inc. (NASDAQ:EXEL), Gilead Sciences Inc. (NASDAQ:GILD), Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Baxalta Incorporated (NYSE: BXLT) announced that the Centers for Medicare and Medicaid Services (CMS) have expanded coverage to include in-home use of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], a treatment for adults with primary immunodeficiency (PI).Baxalta Incorporated (NYSE:BXLT) belongs to Healthcare sector. Its weekly performance is 21.88%. On last trading day company shares ended up $37.10. Baxalta Incorporated (NYSE:BXLT) distance from 50-day simple moving average (SMA50) is 16.62%.

Exelixis, Inc. (NASDAQ:EXEL) announced that its second quarter 2015 financial results will be released on Tuesday, August 11, 2015 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the results and provide a general business update. The conference call will be accessible via the Internet from the company’s website. Exelixis, Inc. (NASDAQ:EXEL) shares increased 8.17% in last trading session and ended the day at $6.62. EXEL Gross Margin is 91.60% and its return on assets is -63.90%. Exelixis, Inc. (NASDAQ:EXEL) quarterly performance is 131.47%.

Gilead Sciences, Inc. (NASDAQ: GILD) announced that the company’s Board of Directors has declared a cash dividend of $0.43 per share of common stock for the third quarter of 2015. The dividend is payable on September 29, 2015, to stockholders of record at the close of business on September 16, 2015. Future dividends will be subject to Board approval. On 04 August, Gilead Sciences Inc. (NASDAQ:GILD) shares decreased -0.61% and was closed at $118.87. GILD EPS growth in last 5 year was 39.10%. Gilead Sciences Inc. (NASDAQ:GILD) year to date (YTD) performance is 26.57%.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that the pivotal TELESTAR Phase 3 clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ended the last trading day at $12.67. Company weekly volatility is calculated as 10.97% and price to cash ratio as 4.17. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) showed a weekly performance of 47.50%.

Leave a Reply

Your email address will not be published. Required fields are marked *